assay · intermediate · partly written
Reporter gene assay
A reporter gene assay puts an easy-to-measure gene, often a luciferase, under a chosen promoter, so a cell's light reports how strongly that switch was turned on, not what your protein does.
Also called: reporter assay, luciferase reporter assay, luciferase assay, reporter gene screen
The short version
A reporter gene assay does not measure your protein. It measures how hard a chosen stretch of DNA drives a stand-in gene whose product gives off light or colour. Amit's guess is right in shape: this is how a cell-based screen can read pathway activity, as opposed to a viability reagent such as CellTiter-Glo, which reads ATP. The best-documented trap is that the reporter enzyme is itself a drug target. 12
Reported, not yet replicated
What a reporter reports, and what it does not more
The cell is given a construct: a promoter or response element of your choice, joined to the code for an easy-to-measure protein. If the pathway you care about switches that element on, the cell makes more reporter, and the plate reader sees more light. So the signal answers 'was transcription from this element turned up or down?' and nothing else. A change in the target protein's activity that does not reach the promoter is invisible, and anything that changes reporter mRNA, reporter protein lifetime or other factors on the same promoter counts as pathway activity.
A reporter's own enzyme chemistry is part of the readout. Inhibit the reporter enzyme and a cell can look inhibited; stabilise it and the cell can look activated. 123
Reported, not yet replicated
His guess, in his words more
He said: "I've seen high-throughput screening done for Cell Titer-Glo, which just tells you if a cell is alive or not. Again, I guess you have some sort of reporter gene, and you're using that to measure activity. I'm not sure." 4
Amit's hypothesis
How his guess fits the evidence more
Right in shape: a reporter gene is how a cell-based screen reads pathway activity. One correction: what it reads is transcription from the chosen element, not the activity of a protein. A viability reagent such as CellTiter-Glo is a different readout (see the linked viability-assay record), and the two are often combined because a viability read is the control for a common reporter artefact: dead cells make less reporter. That pairing is our reading, and no source opened in this run states it for CellTiter-Glo specifically. 52
Our inference
Known artefacts, with the primary evidence more
1. The reporter enzyme is a target. NCGC profiled 360,864 compounds against firefly luciferase: 12% inhibited it. In Tox21, luciferase inhibition was the commonest of the interference types measured, at up to 9.9% of 8,305 chemicals (red autofluorescence was the lowest, at 0.5%). 2. Inhibitors can look like activators. Some FLuc inhibitors protect the enzyme from breakdown in the cell, so its levels rise and the signal goes up. This was first attributed to transcriptional activation and is now attributed mainly to stabilisation of the enzyme. 3. Cytotoxicity read as inhibition. Across 32 Tox21 assays about 8% of compounds were affected by cytotoxicity, the major confounder there. 4. The control reporter is not neutral. Curcumin raised Renilla expression from the SV40 promoter but not from CMV or HSV-TK, so normalising to the SV40 control gave a different answer from the other two. 5. Overexpression and promoter context are named risks in the secondary literature, but no source opened in this run measures them in a drug screen.
How practitioners check: a purified-enzyme counter-screen against the reporter, a second unrelated reporter (as in the PTC124 case), a viability read in the same well, and for the control, two control promoters. 216573
Reported, not yet replicated
A worked example: PTC124 more
Welch and colleagues at PTC Therapeutics described PTC124 as a readthrough drug found with nonsense-containing reporters. NCGC then showed PTC124 inhibits firefly luciferase with an IC50 of 7 +/- 1 nM, that the related compounds' FLuc inhibition tracked their activity in the FLuc cell assay, and that with Renilla luciferase as reporter they had no nonsense-suppression activity and no effect on the enzyme. The authors write that the discovery 'may have been biased by its direct effect on the FLuc reporter'. A review adds that PTC124 is converted by FLuc, in the presence of ATP, into PTC124-AMP, a high-affinity multi-substrate inhibitor. The lesson the authors draw is to run the appropriate control assays before interpreting HTS results. Whether the drug's clinical record bears on this is not covered by any source opened here. 831
Reported, not yet replicated
Where it sits in the cascade more
It is a cell-based, pathway-level readout used in hit discovery and hit-to-lead: it can screen a library without knowing the target, then needs counter-screens (a purified-enzyme test, a second reporter, a viability read) before the hits are trusted. The Tox21 ER programme shows the scale: two reporter lines against about 10,000 chemicals, with a robotic platform able to do the library in triplicate in a week. 9102
Reported, not yet replicated
Cost more
No cost range with a basis and date could be sourced in this run, so the cost field is left out. The only price found was one university core's internal rate for generic 384-well HTS, which is not reporter-specific and whose source was not opened; it is not used. 10
Unverified: from our own report, source not opened
Question answered
Does this compound, in a living cell, push a chosen pathway or response element to switch a gene on or off? It reads out transcription from a promoter the experimenter picked, so it can find pathway modulators without knowing which protein they hit. It does not say that the protein you care about changed activity. 29
Reported, not yet replicated
Readout physical
Light (luciferases), fluorescence (fluorescent proteins) or a colour ratio (beta-lactamase) made by an enzyme or protein the cell was engineered to express from the chosen promoter. For a firefly luciferase the plate reader counts photons after lysis and addition of substrate; the number is the amount of reporter enzyme still active, not the amount of messenger RNA. 1119
Reported, not yet replicated
Not measured
The activity, abundance or location of the native protein; anything the construct's promoter does not respond to; and which step upstream of the promoter the compound acted on. Worse, the readout also carries the reporter enzyme's own chemistry: a compound that inhibits or stabilises the reporter enzyme looks like a pathway effect, and a compound that kills cells lowers the signal. The reporter has its own binding site, and a screen can select for compounds that bind it. 1235
Reported, not yet replicated
Setting
Where in cascade
Throughput
Large qHTS platforms run it at library scale: the Tox21 robotic platform can screen about 10,000 environmental chemicals in triplicate in a week, and two reporter-gene lines (ER-luc, ER-bla) were run against that library. That is a government robotic platform, not a typical lab. The throughput class is our reading of that figure; no source opened gives a typical academic or company rate. 109
Our inference
Time per run
Not established from sources opened in this run. The cell must be exposed to the compound long enough to transcribe and accumulate reporter, which is the slow part (hours to days, depending on reporter half-life); the report this record draws on did not find a sourced typical turnaround for a whole reporter primary screen. 1
Unverified: from our own report, source not opened
Engineerable variants
Firefly luciferase (FLuc)
The workhorse. Needs luciferin and ATP, so the cell is lysed and a detection reagent added; it is also the reporter whose inhibitors are best catalogued, and an inhibitor can stabilise it and so look like an activator. Details of the substrate chemistry and half-life figures come from the review's full text, which was not opened here. 12
Unverified: from our own report, source not opened
Renilla luciferase and a second, control reporter
A second luciferase with an unrelated substrate, used as an internal control or as an orthogonal check. In the PTC124 case, nonsense suppression was seen with firefly luciferase but not with Renilla luciferase. Renilla is not a neutral control: curcumin changed Renilla expression from the SV40 promoter but not from CMV or HSV-TK. 37
Reported, not yet replicated
NanoLuc and secreted luciferases
NanoLuc is a 19 kDa engineered shrimp luciferase using the substrate furimazine. Its authors (Promega) report about 150-fold greater specific activity than firefly or Renilla luciferase in glow-type assays and a signal half-life over 2 hours, and that a signal sequence lets it be read from the culture medium without lysing cells. These are vendor-authored claims. 11
Reported, not yet replicated
Beta-lactamase ratio reporter (bla)
Used alongside luciferase in the Tox21 estrogen-receptor screen: the HEK293 ER-bla line used a transfected partial receptor, the BG1 ER-luc line an endogenous full-length receptor. Both predicted well on 39 reference compounds; luc was more sensitive and bla more specific. The substrate chemistry (cleavage of a FRET substrate, readout as a blue/green ratio) was not opened here. 9
Reported, not yet replicated
Stable lines, transient transfection and endogenous knock-in
A construct can be transfected for a day or two, integrated and selected as a stable line, or inserted by genome editing into the native gene's regulatory region so that it follows the real promoter in its real context. The atlas has not opened a source that compares these in a drug screen; the choice is a trade-off the reader should ask about. 9
Unverified: from our own report, source not opened
Use cases
PTC124 (ataluren), PTC Therapeutics
PTC Therapeutics reported PTC124 as a compound that promotes read-through of premature stop codons, with activity 'optimized using nonsense-containing reporters', and dystrophin restoration in muscle cells and mdx mice. NCGC later found that PTC124 is a very potent firefly luciferase inhibitor (IC50 7 +/- 1 nM), that FLuc inhibition potency of related oxadiazoles tracked their activity in the FLuc nonsense-codon assay, and that none of them suppressed nonsense codons when Renilla luciferase was the reporter. The authors conclude the initial discovery 'may have been biased' by a direct effect on the FLuc reporter. What the reporter assay decided: PTC124 was originally identified in a cell-based FLuc assay, and a counter-screen with a second reporter then showed the reporter was part of the answer. Clinical evidence on the drug is a separate question not covered here. 831
Reported, not yet replicated
Tox21 10K library, estrogen receptor alpha
The US Tox21 programme screened about 10,000 environmental chemicals and drugs against ER-alpha with two reporter-gene lines (BG1 ER-luc, HEK293 ER-bla) in qHTS format. Both lines were over 80% predictive on 39 reference compounds. It decided a profile of which chemicals interact with the ER-alpha pathway, which is toxicology, not a drug lead. 9
Reported, not yet replicated
ML role
Does
Machine-learning models trained on Tox21 interference screens predict from chemical structure whether a compound inhibits luciferase or is autofluorescent, with accuracies of about 80% (the InterPred tool). Used as a filter, it flags likely reporter hitters before a counter-screen is spent on them. 6
Reported, not yet replicated
Cannot
A structure model cannot fix what belongs to the experiment rather than the compound: a construct that reads the wrong promoter, a cytotoxicity-driven drop in signal, or a normalising reporter that the compound itself moves. Models trained on public luciferase-assay data also inherit the reporter's bias: an editorial on luciferase inhibitor bias warns about this, but the editorial text was not opened here, so its figures are not used. Whether a luciferase-inhibition model transfers across assay conditions (substrate level changes which compounds count as inhibitors) is untested in any source opened. 6122
Our inference
Teach this
In one sentence
A reporter gene assay shows how strongly a chosen switch in the DNA was turned on, by making the cell light up a stand-in gene, and what it shows is as much about the stand-in's chemistry as about your biology. 23
Reported, not yet replicated
The five-minute version
Pick the switch (promoter or response element) your pathway should act on and put a luciferase gene after it. Treat cells with compounds and read the light. More light means more transcription from that switch. Then check the control: luciferase is itself a drug target (12% of one large library inhibited it), inhibitors can raise the light by stabilising the enzyme, dead cells give less light, and the internal control can be moved by the compound. The PTC124 story is the cautionary tale: a hit that a second reporter showed was acting on the first. 2357
Reported, not yet replicated
The common wrong idea
The light measures how active my target protein is.
It measures how much a chosen promoter was transcribed, plus whatever the reporter enzyme itself does with your compound.
The one citation to hand over: 3
Still open here
- Cost: no per-well, per-screen or per-campaign range with a basis and date was sourced. The one lead, an academic core's internal 384-well HTS rate, was not opened.
- Time per run and typical plate format for a reporter primary screen: no source opened gives them. The 1536-well format claim rests on a full text nobody has opened.
- Full-text figures not opened (only abstracts): Thorne 2012 (43,885 inhibitors, 168 under 100 nM, 65% and 25% signal increase), Huang 2014 hit rates (5.63% vs 10.36%), Borrel 2020 (6.6% of chemicals in the results text, external accuracy), Thorne 2010 review (reporter table, half-lives).
- Beta-lactamase, GFP and secreted-reporter chemistry (what each emits or converts) and the knock-in versus plasmid comparison were not opened from primary papers; marked unverified or inferred.
- The historic origin (Gorman 1982 CAT reporter; de Wet 1987 luciferase) has not been opened, so before_after is left out.
- Real campaigns: only PTC124 and the Tox21 ER programme are documented. Other named pharma primary screens with primary sources were not found.
- Does a luciferase-inhibition model transfer between assays with different substrate levels, and how large is the inhibitor bias in public luciferase data (the Yonchev and Bajorath editorial was not opened)?
Not yet written: Sample prep, Conditions, Cost, Before after, Capital, Emerging, Data availability.
Linked from
Sources
- Thorne N, Inglese J, Auld DS. Illuminating insights into firefly luciferase and other bioluminescent reporters used in chemical biology. Chemistry & Biology 17(6):646-657 (2010). review; opened 2026-11-17 all records citing this
- Thorne N, Shen M, Lea WA, et al.. Firefly luciferase in chemical biology: a compendium of inhibitors, mechanistic evaluation of chemotypes, and suggested use as a reporter. Chemistry & Biology 19(8):1060-1072 (2012). paper; opened 2026-11-17 all records citing this
- Auld DS, Thorne N, Maguire WF, Inglese J. Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression. PNAS 106(9):3585-3590 (2009). paper; opened 2026-11-17 all records citing this
- Amit's dictation of 2026-11-17: what the atlas must contain. Kept in the atlas repository; not published.
- Hsieh JH, Sedykh A, Huang R, Xia M, Tice RR. A data analysis pipeline accounting for artifacts in Tox21 quantitative high-throughput screening assays. Journal of Biomolecular Screening 20(7):887-897 (2015). paper; opened 2026-11-17 all records citing this
- Borrel A, Huang R, Sakamuru S, et al.. High-throughput screening to predict chemical-assay interference. Scientific Reports 10:3986 (2020). paper; opened 2026-11-17 all records citing this
- Wu GQ, Wang X, Zhou HY, et al.. Evidence for transcriptional interference in a dual-luciferase reporter system. Scientific Reports 5:17675 (2015). paper; opened 2026-11-17 all records citing this
- Welch EM, Barton ER, Zhuo J, et al.. PTC124 targets genetic disorders caused by nonsense mutations. Nature 447:87-91 (2007). paper; opened 2026-11-17 all records citing this
- Huang R, Sakamuru S, Martin MT, et al.. Profiling of the Tox21 10K compound library for agonists and antagonists of the estrogen receptor alpha signaling pathway. Scientific Reports 4:5664 (2014). paper; opened 2026-11-17 all records citing this
- Attene-Ramos MS, Miller N, Huang R, et al.. The Tox21 robotic platform for the assessment of environmental chemicals: from vision to reality. Drug Discovery Today 18(15-16):716-723 (2013). review; opened 2026-11-17 all records citing this
- Hall MP, Unch J, Binkowski BF, et al.. Engineered luciferase reporter from a deep sea shrimp utilizing a novel imidazopyrazinone substrate. ACS Chemical Biology 7(11):1848-1857 (2012). paper; opened 2026-11-17 all records citing this
- Yonchev D, Bajorath J. Inhibitor bias in luciferase-based luminescence assays. Future Science OA 6(8):FSO594 (editorial) (2020). paper; opened 2026-11-17 all records citing this
Where it sits on the map
History of this record (10)
This record has been changed 10 times, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.
- Throughput class
- high
- Status
- partly written
- Last updated
- 2026-11-19
- Record
- content/assays/reporter-gene-assay.json